<DOC>
	<DOCNO>NCT01649297</DOCNO>
	<brief_summary>The aim study investigate efficacy safety two dos ( high low ) empagliflozin add-on therapy metformin patient type 2 diabetes mellitus ( T2DM ) insufficient glycaemic control . Both dos may give daily split twice daily dosage . This result 4 different dosage regimen empagliflozin ( high dose daily split vs. low dose daily split ) . This do evaluate whether twice daily dose regimen empagliflozin result loss efficacy relative daily dose give top metformin background therapy .</brief_summary>
	<brief_title>A 16 Weeks Study Efficacy Safety Two Doses Empagliflozin ( BI 10773 ) ( Once Daily Versus Twice Daily ) Patients With Type 2 Diabetes Mellitus Preexisting Metformin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : 1. confirm diagnosis T2DM 2 . Glycated hemoglobin ( HbA1c ) &gt; =7.0 &lt; =10/0 % Visit 1 3 . Metformin therapy ( least 1500 mg/day , BID ) 4. age &gt; =18 Visit 1 5. body mass index &lt; =45 kg/m2 Exclusion criterion : 1. estimate creatinine clearance rate ( eCCr ) &lt; 60 ml/min ( CockcroftGault formula ) screen and/or runin 2. confirm glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast placebo runin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>